i
Cluster of cases of thrombotic thrombocytopenic purpura (TTP) associated with intravenous nonmedical use of Opana ER®
-
10/26/12
Series: HAN ; 331
Details:
-
Corporate Authors:
-
Description:October 26, 2012, 18:00 ET (6:00 PM ET)
CDCHAN-00331-2012-26-10-UPD-N
The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are working with the Tennessee Department of Health (TDH) on investigating a cluster of at least 12 patients with thrombotic thrombocytopenic purpura (TTP) who have injected the opioid pain reliever, Opana ER® (oxymorphone extended-release), for nonmedical reasons since February, 2012. Investigation is ongoing.
This HAN notice provides information on the following:
• Status of the investigation
• Background on T T P and Opana ER®
• Recommendations
• Case definition
-
Subject:
-
Series:
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
Supporting Files
-
No Additional Files
More +